Nymox Pharmaceutical CORP (NYMXF) — 20-F Filings
All 20-F filings from Nymox Pharmaceutical CORP. Browse 2 Foreign Annual Report reports with AI-powered summaries and risk analysis.
20-F Filings (2)
-
NYMOX Remains Revenue-Less, Pushing R&D Amid Funding Concerns
— Jun 3, 2025 Risk: high
NYMOX PHARMACEUTICAL CORP reported no revenue for the fiscal year ended December 31, 2024, consistent with the prior two years, indicating a pre-commercial or r -
Nymox Pharma Files 20-F for FY2023
— Aug 29, 2024 Risk: medium
Nymox Pharmaceutical Corp. filed its 20-F for the fiscal year ending December 31, 2023. The company is involved in the development of therapeutics for enlarged
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX